ID: ALA2165450

Max Phase: Preclinical

Molecular Formula: C8H12N2O2

Molecular Weight: 168.20

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(OC[C@@H]2CCN2)no1

Standard InChI:  InChI=1S/C8H12N2O2/c1-6-4-8(10-12-6)11-5-7-2-3-9-7/h4,7,9H,2-3,5H2,1H3/t7-/m0/s1

Standard InChI Key:  VVAKKXKBWCMSRO-ZETCQYMHSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 168.20

Molecular Weight (Monoisotopic): 168.0899

AlogP: 0.72

#Rotatable Bonds: 3

Polar Surface Area: 47.29

Molecular Species: BASE

HBA: 4

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 9.65

CX LogP: 0.56

CX LogD: -1.66

Aromatic Rings: 1

Heavy Atoms: 12

QED Weighted: 0.72

Np Likeness Score: -0.99

References

1. Yu LF, Tückmantel W, Eaton JB, Caldarone B, Fedolak A, Hanania T, Brunner D, Lukas RJ, Kozikowski AP..  (2012)  Identification of novel α4β2-nicotinic acetylcholine receptor (nAChR) agonists based on an isoxazole ether scaffold that demonstrate antidepressant-like activity.,  55  (2): [PMID:22148173] [10.1021/jm201301h]

2. Yu LF, Zhang HK, Gunosewoyo H, Kozikowski AP..  (2012)  From α4β2 Nicotinic Ligands to the Discovery of σ1 Receptor Ligands: Pharmacophore Analysis and Rational Design.,  3  (12): [PMID:23641311] [10.1021/ml3002715]

Source

Source(1):

• Scientific Literature